Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586111 | 1.00 | RAF1 (0.50) | RAF1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL1476029 | 0.82 | RAF1 (0.47) | RAF1 | |
| SCHEMBL18921321 | 0.81 | RAF1 (0.53) | RAF1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL18921318 | 0.81 | RAF1 (0.53) | RAF1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL1476741 | 0.79 | RAF1 (0.50) | RAF1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL20489980 | 0.79 | CYP2A6 (0.40) | RAF1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29951866 | 0.79 | CYP2A6 (0.40) | RAF1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL746371 | 0.78 | CYP11B2 (0.49) | CYP11B1CYP11B2 | |
| Ethylene Glycol SCHEMBL11190757 | 0.78 | RAF1 (0.38) | RAF1 | |
| SCHEMBL936524 | 0.77 | CYP11B1 (0.47) | RAF1CYP11B1CYP11B2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4313292-B1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARM SPA (IT) | 2026-02-18 | — | — | EP | disclosed |
| EP-4313994-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-05 | — | — | EP | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-20 | — | — | US | disclosed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| CN-117777009-A | Compound darmorkvir and application thereof | 上海市重大传染病和生物安全研究院 | 2024-03-29 | — | — | CN | disclosed |
| EP-4313292-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120434-A | Indoline derivatives as DDR1 and DDR2 inhibitors | 奇斯药制品公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1509515-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003097806-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-4393212-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1983-07-12 | — | — | US | disclosed |
| US-4294969-A | COUPLING N-BROMOSUCCINIMIDE AND A 2-BROMOPYRIDINE | MERCK & CO., INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4279913-A | ANTIARRYTHMIA, HYPOTENSIVE | MERCK & CO., INC. (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | DDR1, DDR2, DDRGK1 | RAF1 2117/4885CYP11B1 4317/4885CYP11B2 4096/4885 |
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | DDR1, DDR2, DDRGK1 | RAF1 445/4885CYP11B1 3500/4885CYP11B2 3869/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | RAF1 686/4885CYP11B1 1407/4885CYP11B2 2028/4885 |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | RAF1 550/4885CYP11B1 4395/4885CYP11B2 4543/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | RAF1 586/4885CYP11B1 263/4885CYP11B2 513/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | RAF1 468/4885CYP11B1 149/4885CYP11B2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.